7 citations
,
July 2019 in “The Journal of Dermatology” Terbinafine effectively treated kerion celsi despite disrupted immune responses.
December 2024 in “Kufa Medical journal” Higher levels of IL-17A and IL-2 are linked to alopecia areata.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
20 citations
,
March 2019 in “Case Reports in Dermatology” IL-17 inhibitors for psoriasis may cause unexpected hair loss.
2 citations
,
January 2024 in “Advances in Dermatology and Allergology” S100A7 and IL-17 may contribute to inflammation in lichen planopilaris.
June 2023 in “Benha Journal of Applied Sciences” Targeting IL-17 could help treat pattern hair loss.
December 2025 in “Nature Communications” Blocking IL-17a can improve age-related smell loss in mice.
April 2023 in “The Egyptian Journal of Hospital Medicine” Higher Interleukin 17A levels may indicate more severe alopecia areata.
3 citations
,
May 2020 in “JAAD Case Reports” Two patients with psoriasis grew extra hair after using certain psoriasis medications.
1 citations
,
May 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” Certain gene variations are linked to alopecia areata.
September 2025 in “Diseases” Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.
57 citations
,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
19 citations
,
August 2018 in “JAMA dermatology” Mesenchymal stem cells in people with Hidradenitis Suppurativa are more inflammatory, possibly contributing to the disease.
12 citations
,
March 2016 in “BBA clinical” Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.
1 citations
,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
1 citations
,
January 2014 in “The Journal of Dermatology” A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.
July 2024 in “Journal of Investigative Dermatology” Hair follicles are crucial for maintaining skin barrier function.
April 2023 in “Journal of Investigative Dermatology” Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.
22 citations
,
March 2018 in “American Journal of Clinical Dermatology” New acne treatments show promise as alternatives to traditional therapies.
78 citations
,
June 2021 in “Dermatology and Therapy” Future acne treatments should aggressively target inflammation to prevent scarring.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
6 citations
,
October 2021 in “Biomedical Research and Therapy” Alopecia areata patients have higher levels of IL-6 and TNF-α.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
59 citations
,
June 2023 in “Nature Aging” Blocking IL-17 signaling may reduce skin inflammation and delay aging.
14 citations
,
January 2020 in “Advances in Dermatology and Allergology” Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.
September 2024 in “South Eastern European Journal of Public Health” Alopecia areata patients have higher IgE and IL-13 levels, suggesting immune involvement.
3 citations
,
March 2021 in “JAAD case reports” Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
February 2024 in “Curēus” Secukinumab can cause hair loss, which may improve after stopping the medication.